Moderna (MRNA) has been one the past year’s most successful stories. The change between the high-flying biotech’s standing a year ago compared to its current position, was easy to tell in the company’s latest quarterly statement. In 4Q20, Moderna delivered revenue of $571 million, a far cry from the $14 million in sales it reported in the same period last year. The figure also came in well ahead of the Street’s call for $279.4 million. Of course, the massive change was due to the sales of its Covid-19 vaccine mRNA-1273, which was granted Emergency Use Authorization (EUA) in December. The vaccine generated sales of almost $200 million.
https://www.tipranks.com/news/article/moderna-stock-may-still-be-undervalued-by-30-analyst-says